University Hospitals Coventry and Warwickshire (UHCW) NHS Trust is to lead a clinical trial of a novel device aimed at addressing miscarriage symptoms.
John Grimm, Vice President of Strategy and Business Development at Entrust, shares his advice on how health organisations can minimise the chances of a security breach at a time when resources are stretched more than ever.
Timothy Kwok, Professor at The Chinese University of Hong Kong, tells us about the Electronic Cognitive Screen (EC-Screen) that gives a brief and user-friendly digital cognitive test for the detection of dementia in older people.
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.
The independent experts of the FDA say the Pfizer vaccine is good to go, which means that the COVID vaccine should be formally approved in a matter of days.
In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Here, we look into the many ways in which medical and safety technology manufacturer Dräger has been stepping up to help its customers through the COVID-19 crisis.
Andrea Ammon, Director at the European Centre for Disease Prevention and Control, takes us on a journey from COVID-19 to the future of public health surveillance.
Dr Ganesan Baranidharan, consultant in anaesthesia and pain medicine at the Leeds Teaching Hospitals NHS Trust, explains the power of neuromodulation for managing chronic pain and explains why comprehensive evidence is needed.
Leading pancreatic cancer experts Professor Matthias Löhr and Professor Monique van Leerdam of United European Gastroenterology’s (UEG) Public Affairs Committee discuss the importance of early diagnosis and the latest developments in treatment for pancreatic cancer.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
